Seres Therapeutics, Inc. (MCRB)’s Trend Up, Especially After Today’s Strong Session

April 17, 2018 - By Michael Collier

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) is a huge mover today! The stock increased 9.06% or $0.695 during the last trading session, reaching $8.365. About 254,887 shares traded or 70.46% up from the average. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 31.05% since April 17, 2017 and is downtrending. It has underperformed by 42.60% the S&P500.
The move comes after 9 months positive chart setup for the $340.02M company. It was reported on Apr, 17 by We have $9.12 PT which if reached, will make NASDAQ:MCRB worth $30.60 million more.

Analysts await Seres Therapeutics, Inc. (NASDAQ:MCRB) to report earnings on May, 3. They expect $-0.72 EPS, down 14.29 % or $0.09 from last year’s $-0.63 per share. After $-0.71 actual EPS reported by Seres Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.41 % negative EPS growth.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 2 analysts covering Seres Therapeutics (NASDAQ:MCRB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics had 5 analyst reports since October 19, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, January 11 by Oppenheimer. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, March 8. The company was maintained on Thursday, October 19 by Cantor Fitzgerald. The company was maintained on Wednesday, November 8 by Cantor Fitzgerald. The rating was maintained by Oppenheimer with “Buy” on Tuesday, March 20.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $340.02 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.